Latest news with #surgicalrobotics
Associated Press
24-06-2025
- Business
- Associated Press
cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer
GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as Chief Executive Officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. 'The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor,' said Jim Alecxih, CEO of Virtual Incision. 'I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, Hospital Outpatient Department (HOPD) and Ambulatory Surgery Centers (ASC) settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers.' 'We are excited for this next significant phase and stage in the life of Virtual Incision's important journey to continue to bring 'MIRA', the miniature innovative robot, to the world,' said Dave Blue, Director, cultivate(MD) Capital Funds. Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About cultivate(MD) cultivate(MD) is a medical device venture capital firm dedicated to advancing healthcare innovation. With a keen focus on cutting-edge medical technologies, cultivate(MD) supports companies that show the potential to revolutionize healthcare delivery and patient care. For more information, visit: About the MIRA Surgical System MIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit: Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View original content to download multimedia: SOURCE cultivate(MD)
Yahoo
24-06-2025
- Business
- Yahoo
cultivate(MD) Announces Portfolio Company, Virtual Incision Corporation, Appoints Jim Alecxih as Chief Executive Officer
GRAND RAPIDS, Mich., June 24, 2025 /PRNewswire/ -- cultivate(MD), a leading medical device venture capital company, is pleased to announce that its portfolio company, Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, has appointed Jim Alecxih as Chief Executive Officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. "The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor," said Jim Alecxih, CEO of Virtual Incision. "I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, Hospital Outpatient Department (HOPD) and Ambulatory Surgery Centers (ASC) settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers." "We are excited for this next significant phase and stage in the life of Virtual Incision's important journey to continue to bring "MIRA", the miniature innovative robot, to the world," said Dave Blue, Director, cultivate(MD) Capital Funds. Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Fast Company's World's Most Innovative Companies SXSW Innovation Award Fierce MedTech's Fierce 15 Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About cultivate(MD)cultivate(MD) is a medical device venture capital firm dedicated to advancing healthcare innovation. With a keen focus on cutting-edge medical technologies, cultivate(MD) supports companies that show the potential to revolutionize healthcare delivery and patient care. For more information, visit: About the MIRA Surgical SystemMIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual IncisionVirtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit: Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View original content to download multimedia: SOURCE cultivate(MD) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Times
22-06-2025
- Health
- Times
A robot surgeon? I'll put my money on that
T hank you for waiting, the robot will see you now. Nine in ten keyhole operations won't need a human surgeon in the room within the next decade, according to the NHS. One in five operations are already carried out by robots, guided remotely, to improve outcomes while cutting costs. Science fiction is becoming surgical fact because robotic-assisted surgery can mean smaller incisions, reduced scarring and quicker recovery. There's no need to take my word for it: Sir Jim Mackey, the chief executive of the NHS, said: 'We are using every tool to ensure patients get the best possible treatment. Expanding the use of new tech, such as robotic surgery, will play a huge part.' Wes Streeting, the health and social care secretary, added: 'I know how important this is. The NHS saved my life from kidney cancer with an operation led by a world-class surgeon being helped by a robot.'
Yahoo
18-06-2025
- Business
- Yahoo
Virtual Incision Appoints Jim Alecxih as Chief Executive Officer
Seasoned medtech leader and former Intuitive Surgical executive to accelerate development and commercialization of the company's next-generation MIRA Surgical System platforms and technologies LINCOLN, Neb., June 18, 2025--(BUSINESS WIRE)--Virtual Incision Corporation, the developer of the MIRA Surgical System authorized by the FDA through the De Novo regulatory pathway, today announced the appointment of Jim Alecxih as chief executive officer. Alecxih, a recognized commercial leader in the medical device industry, brings more than 30 years of experience advancing transformative surgical technologies worldwide, including a distinguished tenure at Intuitive Surgical, where he played a pivotal role in the adoption and growth of the da Vinci Surgical System. Virtual Incision is now preparing for the accelerated development and commercialization of their next system, M2, with plans for a series of FDA submissions in various specialties. M2 is a miniaturized, single port surgical robotic system designed to be smart, simple and small, with the potential to minimize the cost and complexity of current mainframe cart-based surgical robotic systems. M2 will be optimized to bring robotic-assisted surgery to hospitals and surgical settings that lack access to surgical robotics technologies. Mr. Alecxih previously served as CEO of DH Medical, an AI software company, and has held executive leadership roles across multiple healthcare startups and growth-stage companies. At Intuitive Surgical, he led U.S. sales and was instrumental in driving adoption of robotic-assisted surgery among hospitals and health systems nationwide. "The opportunity to lead Virtual Incision at this pivotal time is an extraordinary honor," said Jim Alecxih, CEO of Virtual Incision. "I believe deeply in the benefits of robotic-assisted surgery to both patients, surgeons and hospitals. M2 has the potential to dramatically expand access to robotic-assisted surgery in rural hospitals, HOPD and ASC settings, and around the world. Virtual Incision's visionary approach is to ensure that robotic-assisted surgery is more accessible, flexible and scalable for a broader range of operating environments. I'm thrilled to join this talented team and help accelerate our impact on patients and providers." "We are delighted to welcome Mr. Alecxih to Virtual Incision at this significant stage in the company's growth," said Tyler Stowater, partner at Bluestem Capital and Virtual Incision board member. "Mr. Alecxih's exceptional leadership skills and deep industry knowledge make him the ideal person to lead us into our next phase of growth and innovation." Mr. Alecxih joins Virtual Incision at a time of significant momentum. In 2025, the company has been honored as a finalist or winner in three prestigious innovation awards: Fast Company's World's Most Innovative Companies SXSW Innovation Award Fierce MedTech's Fierce 15 Virtual Incision's MIRA Surgical System is designed to offer a portable, scalable solution for minimally invasive procedures with a small footprint and a simple setup. With M2, the company aims to expand clinical capabilities and will continue redefining the future of robotic-assisted surgery. About the MIRA Surgical System MIRA is the world's first miniaturized robotic-assisted surgery (RAS) system. Its small, sleek form factor is designed to offer the benefits of RAS during colectomy procedures without the logistical inefficiencies of traditional mainframe robotics. The easily accessible device weighs approximately two pounds (less than one kg) and offers internal triangulation with shoulders, arms, and infinite wrist roll inside of the body. It can be used in any operating room – a dedicated operating room is unnecessary. With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move between cases. Its conveniently accessible design positions it to be used as a standalone system or a complementary tool for facilities that already own a legacy surgical robotic system. With MIRA, every operating room is RAS-ready. About Virtual Incision Virtual Incision is on a mission to simplify robotic-assisted surgery (RAS), so more patients and their surgeons can access its benefits every day. Headquartered in Lincoln, Nebraska, and holding over two hundred patents and patent applications, the company developed MIRA, the first-of-its-kind miniature RAS system. Virtual Incision's goal is to make every operating room RAS-ready. For more information, visit our website or follow us on LinkedIn. Important Safety Information The MIRA Surgical System is intended for prescription use only. Patients should talk to their doctor to decide if surgery with a MIRA Surgical System is right for them. For important safety information, indications for use, risks, and warnings, please refer to Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View source version on Contacts Media Contact: Ashlynn MeyerVirtual Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
Moon Surgical Discusses Maestro at NVIDIA GTC Paris, Celebrating 1,300+ Procedures in the Past Year and the Power of Physical AI
PARIS and SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- Moon Surgical, the French-American leader in Physical AI for the operating room, today announced its participation at NVIDIA GTC Paris during VivaTech2025. In collaboration with NVIDIA, Moon Surgical is highlighting the Maestro System as a pioneering example of Physical AI in action—empowering surgical teams across the globe. As of today, the Maestro System has supported over 1,500 procedures worldwide, with more than 1,300 of those performed in the past year alone. With the integration of Physical AI—merging perceptive robotics and real-time computing—Maestro has proven its adaptability across 60 different minimally invasive procedures and its growing role in high-volume outpatient care. Physical AI is the integration of perceptive hardware with powerful local computing, enabling software-defined systems to understand and interact with the physical world in real time. From system deployment to procedural subtasks, physical AI combines the forces of robotic devices and agentic AI, it is the infrastructure layer to the operating room. Maestro uses ambient sensing, and robotics powered by NVIDIA Holoscan and NVIDIA IGX technologies to bring this type of capability to the clinical edge — empowering surgical teams to deliver consistent, efficient care. Anne Osdoit, CEO of Moon Surgical, will present a session titled "Reimagining Surgical Robotics as Physical AI Agents for Global Reach" at GTC Paris, spotlighting how generative Physical AI is redefining the role of surgical robotics through simulation and human collaboration. Maestro is designed to enhance—not replace—human expertise, acting as an extension of the surgical team to facilitate coordination, communication, and refined technique during minimally invasive surgery. About Moon Surgical (AI / MIS focused)Moon Surgical is transforming the operating room with Physical AI, seamlessly integrating intelligence and robotics to elevate the capabilities of surgical teams. The Maestro System represents a new category of minimally invasive surgery—expanding the scale at which robotics are delivered into the operating rooms. Instinctive, collaborative, and cost-effective, Maestro empowers teams to deliver exceptional care with greater adaptability and control. Moon Surgical. Inspiring and Innovating the Art of Surgery. For investor and media inquiries, please email us at info@ Check us out at or follow us on LinkedIn. View original content to download multimedia: SOURCE Moon Surgical
